Literature DB >> 18276713

Use of randomised trials to decide when to monitor response to new treatment.

Katy J L Bell1, Les Irwig, Jonathan C Craig, Petra Macaskill.   

Abstract

Mesh：

Year:  2008        PMID： 18276713      PMCID： PMC2244786          DOI： 10.1136/bmj.39476.623611.25

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  A consumer's guide to subgroup analyses.

Authors:  A D Oxman; G H Guyatt
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

3.  Regression to the mean: treatment effect without the intervention.

Authors:  Veronica Morton; David J Torgerson
Journal:  J Eval Clin Pract       Date:  2005-02       Impact factor: 2.431

Review 4.  Monitoring in chronic disease: a rational approach.

Authors:  Paul Glasziou; Les Irwig; David Mant
Journal:  BMJ       Date:  2005-03-19

5.  Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.

Authors:  Lorenz Sellin; Johannes Stegbauer; Petra Laeis; Lars C Rump
Journal:  J Hypertens       Date:  2005-11       Impact factor: 4.844

6.  Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.

Authors:  S R Cummings; L Palermo; W Browner; R Marcus; R Wallace; J Pearson; T Blackwell; S Eckert; D Black
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

7.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

Authors:  Steven R Cummings; David B Karpf; Fran Harris; Harry K Genant; Kristine Ensrud; Andrea Z LaCroix; Dennis M Black
Journal:  Am J Med       Date:  2002-03       Impact factor: 4.965

Review 8.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

9.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245
  9 in total
  3 in total

1.  Patterns and trends of potentially inappropriate high-density lipoprotein cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 to 2014: analysis of linked individual patient data from the Australian Medicare Benefits Schedule and Pharmaceutical Benefits Scheme.

Authors:  Farshid Hajati; Evan Atlantis; Katy J L Bell; Federico Girosi
Journal:  BMJ Open       Date:  2018-03-08       Impact factor: 2.692

2.  Clinical effect modifiers of antibiotic treatment in patients with chronic low back pain and Modic changes - secondary analyses of a randomised, placebo-controlled trial (the AIM study).

Authors:  Lars Christian Haugli Bråten; Lars Grøvle; Ansgar Espeland; Are Hugo Pripp; Margreth Grotle; Christian Helllum; Anne Julsrud Haugen; Anne Froholdt; Mads Peder Rolfsen; Øystein Petter Nygaard; Olav Lutro; Per Martin Kristoffersen; Audny Anke; Elina Iordanova Schistad; Jan Sture Skouen; Jens Ivar Brox; John-Anker Zwart; Kjersti Storheim
Journal:  BMC Musculoskelet Disord       Date:  2020-07-13       Impact factor: 2.362

3.  Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.

Authors:  Katy J L Bell; Andrew Hayen; Petra Macaskill; Les Irwig; Jonathan C Craig; Kristine Ensrud; Douglas C Bauer
Journal:  BMJ       Date:  2009-06-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.